3White K J,Walhne C C, Barker E L. Serotonin transporters: implications for antidepressant drug development[J]. AAPS J,2005.7(2):E421-E433.
4Schechter I, E, Ring R H, Beyer C E,et al. Innovative approaches for lhe development of antidepressant drugs: current and future strategies[J]. NeuroRx,2005,2(4) :590-611.
5Bukh J D. Jorgensen M B, Dana H,el al. Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting[J]. Nord J Psychiatry,2009,63(4) :347-351.
6Ban T A. Pharmacotherapy of depression:a historical analysis [J].J Neural Transm,2001,108(6):707-716.
7Mullins C D, Shaya F T, Meng F,et al. Comparison of first re fill rates anaong users of serlrallne, paroxetine,and citalopram [J]. Clin Ther,2006,28(2):297-305.
8Perna G,Bertani A.Caldirola D.et al. A comparison of citalopram and paroxetine in the treatment of panic disorder:a ran domized,single-blind study[J]. Pharmacopsvchiatry, 2001 34 (3), 85-90.
9Gatti F,Bellini L,Gaserini M,et al.Fluvoxamine alone in the treatment of delusional depression[J].Am J Psychiatry,1996,153(3):414-416.
10Pogosova G V. Zhidko N I, Mikheeva T G, et al, Clinica effectiveness and safety of citalopram in patients with depres sion after myocardial infarction[J]. Kardiologiia, 2003,43(1):24-29.
